Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.98 |
| ▸ | MEN1 | O00255 | 3/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.98 |
| ▸ | MAPT | P10636 | 2/20 | 0.98 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.98 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.98 |
| ▸ | POLB | P06746 | 1/20 | 0.98 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.98 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.98 |
| ▸ | HSPA1A | P0DMV8 | 1/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.98 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.98 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.98 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.98 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.98 |
| ▸ | RAB9A | P51151 | 1/20 | 0.98 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.98 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.98 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.98 |
| ▸ | CXCR6 | O00574 | 11/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13856379 | 1.00 | KMT2A (0.98) | KMT2AMEN1ALDH1A1MAPTKDM4E | |
| Hydrochloric Acid SCHEMBL2114038 | 0.99 | KMT2A (1.00) | KMT2AMEN1ALDH1A1MAPTKDM4E | |
| SCHEMBL3478681 | 0.86 | KMT2A (0.74) | KMT2AMEN1ALDH1A1MAPTKDM4E | |
| SCHEMBL13857044 | 0.75 | KMT2A (0.59) | KMT2AMEN1ALDH1A1MAPTKDM4E | |
| SCHEMBL1667825 | 0.73 | RAB9A (0.73) | KMT2AMEN1ALDH1A1KDM4ECYP1A2 | |
| SCHEMBL2468483 | 0.73 | NPC1 (0.71) | KMT2AMEN1ALDH1A1MAPTRAB9A | |
| SCHEMBL31118803 | 0.73 | CXCR6 (1.00) | CXCR6 | |
| SCHEMBL22891539 | 0.73 | CXCR6 (1.00) | CXCR6 | |
| SCHEMBL11241115 | 0.72 | RAB9A (0.75) | KMT2AMEN1ALDH1A1KDM4ECYP1A2 | |
| SCHEMBL8987225 | 0.72 | MEN1 (0.84) | KMT2AMEN1ALDH1A1POLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095032-A1 | METHODS FOR TREATING LEUKEMIA AND MYELODYSPLASTIC SYNDROME, AND METHODS FOR IDENTIFYING AGENTS FOR TREATING SAME | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2012-04-19 | — | — | US | disclosed |
| US-20090118135-A1 | METHODS AND COMPOUNDS FOR REGULATING APOPTOSIS | THE BURNHAM INSTITUTE (US) | 2009-05-07 | — | — | US | disclosed |
| US-20090105240-A1 | Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2009-04-23 | — | — | US | disclosed |
| US-20090105240-A1 | Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105240-A1 | Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same | MCL1, AS3MT, MYADM | KMT2A 848/4885MEN1 1901/4885ALDH1A1 210/4885 |
| US-20090118135-A1 | METHODS AND COMPOUNDS FOR REGULATING APOPTOSIS | BCL2, BAX, BAD | KMT2A 4047/4885MEN1 4323/4885ALDH1A1 3724/4885 |
| US-20120095032-A1 | METHODS FOR TREATING LEUKEMIA AND MYELODYSPLASTIC SYNDROME, AND METHODS FOR IDENTIFYING AGENTS FOR TREATING SAME | MCL1, AS3MT, MYADM | KMT2A 848/4885MEN1 1901/4885ALDH1A1 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.